Advances in Anticancer Immunotoxin Therapy
Advances in Anticancer Immunotoxin Therapy
复制标题
DOI：
10.1634/theoncologist.2014-0358
复制
发表时间：
2015-02-01
期刊：
影响因子：
5.8
通讯作者：
Pastan, Ira
中科院分区：
文献类型：
--
作者：
Alewine, Christine;Hassan, Raffit;Pastan, Ira
免疫毒素是一种新型的抗体偶联疗法，目前在临床开发的各种恶性肿瘤。它们由基于抗体的靶向结构域与用于细胞杀伤的细菌毒素有效载荷融合组成。免疫毒素通过抑制蛋白质合成杀死细胞，这是一种对分裂和非分裂细胞都有毒的独特作用机制。免疫毒素的设计和给药的最新进展正在克服该领域的历史挑战，导致对这些治疗方法的重新关注。
Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing. Immunotoxins kill cellsbyinhibiting protein synthesis, aunique mechanism of action that is toxic to both dividing and nondividing cells. Recent advances in the design and administration of immunotoxins are overcoming historical challenges in the field, leading torenewedinterest in these therapeutics.